Physician profile
Michael Kitchell
NPI 1932490554
$2,968.05
in general payments reported to CMS, 2019-2025
25 companies · $262 in 2025
The $262 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $161 · 2021: $1,020 · 2022: $612 · 2023: $449 · 2024: $464 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,175.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $556.34 | 2020-2025 | |
| Novo Nordisk INC | $445.60 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.75 | 2020-2025 | Jardiance |
| Astellas Pharma US INC | $236.64 | 2022-2025 | Veozah |
| Merck Sharp & Dohme LLC | $211.84 | 2021-2023 | Dificid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $199.24 | 2020-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $161.94 | 2021-2025 | Farxiga, Airsupra |
| Amgen INC. | $132.78 | 2021-2022 | |
| Exact Sciences Corporation | $128.04 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $120.90 | 2021-2024 | Mounjaro, Zepbound |
| Pfizer INC. | $106.17 | 2021-2025 | |
| Axsome Therapeutics, INC. | $68.73 | 2023 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $52.45 | 2022 | |
| Abbott Laboratories | $37.16 | 2022-2023 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $30.58 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $28.02 | 2021 | |
| Allergan, INC. | $24.83 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $19.54 | 2021 | |
| Abiomed | $18.14 | 2025 | |
| Medtronic, INC. | $18.08 | 2024 | Intellis Adaptivestim |
| Shield Therapeutics INC | $16.94 | 2025 | |
| Hologic Sales and Service, LLC | $16.59 | 2021 | |
| Seqirus USA INC | $16.44 | 2024 | Flucelvax, Fluad |
| Sanofi-Aventis U.S. LLC | $15.97 | 2025 | |
| Phathom Pharmaceuticals, INC. | $15.34 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.